# Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

> **NCT01949662** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 93 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Lorazepam
- **DRUG:** Placebo
- **DRUG:** Haloperidol decanoate
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT01949662
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01
- **Primary completion:** 2016-08-26
- **Final completion:** 2028-01-01
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949662, "Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01949662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*